Faruqi & Faruqi, LLP Investigates Altimmune Claims as Investor Deadline Approaches

Investigating Potential Securities Claims Against Altimmune

As the October 6, 2025 deadline approaches, leading national securities law firm Faruqi & Faruqi, LLP is actively investigating potential claims on behalf of investors in Altimmune, Inc. Recent events have raised significant concerns regarding the company's performance, prompting further scrutiny from investors.

Overview of Altimmune, Inc.

Altimmune, Inc. (NASDAQ: ALT) is a biopharmaceutical company focused on developing immune-modulating therapies for a variety of diseases. Established in the mid-2000s, Altimmune aims to provide innovative solutions in the healthcare landscape. However, recent events have severely impacted the company's stock and raised questions about its operational integrity.

Recent Developments and Investigation

On June 26, 2025, Altimmune released a press statement outlining the topline results of its IMPACT Phase 2b MASH trial, which focused on Pemvidutide for treating MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease). Unfortunately, the findings revealed a significant failure to meet statistical significance in the primary endpoint related to fibrosis reduction, despite prior expectations set by the company. This raised eyebrows, as Altimmune had previously portrayed a positive outlook leading up to the results announcement.

Consequently, on the day following the release of the results, Altimmune's stock plummeted from a closing price of $7.71 to $3.61, marking an astonishing drop of over 53.2% in just a single trading session. Such a sharp decline has led many investors to question their standing and seek redress. The law firm Faruqi & Faruqi is now urging those who sustained losses exceeding $75,000 during the period from August 10, 2023, to June 25, 2025, to reach out and discuss their potential legal options.

Importance of Acting Promptly

The warnings about the deadline for claims are a crucial aspect of this process. Investors who believe they have suffered losses are encouraged to consider the role of lead plaintiffs in a federal securities class action case. The appointed lead plaintiff will represent the interests of the entire class in litigation against Altimmune. This means it’s vital to act quickly to ensure that you do not miss the opportunity to seek legal recourse, especially given the imminent deadline.

Furthermore, the law firm represents not only large investors but also those who may have smaller investments but still hold valid claims against the company due to the impact of the unfavorable trial results on stock prices. Investment in stock is inherently risky, but being misled about a company’s performance can exacerbate those risks significantly.

Contact and Further Information

Faruqi & Faruqi strongly encourages anyone with additional information about Altimmune’s practices or the recent trial results to step forward. This includes former employees, whistleblowers, and other stakeholders who can provide relevant insights into the company’s operations and communications leading up to the trial results. Potential plaintiffs or those with insights can contact Faruqi & Faruqi directly to explore their legal rights further.

For more information on this case, or if you wish to discuss your personal situation, you can contact Faruqi & Faruqi partner Josh Wilson directly via the firm’s hotline. They maintain a commitment to a confidential and comprehensive approach, ensuring that all communications regarding your inquiry are handled with the utmost discretion and professionalism.

As the deadline approaches, awareness and timely action are key components to seeking any form of restitution from Altimmune. Investors who wish to be proactive can find more details by visiting the law firm's specific page dedicated to Altimmune at Faruqi & Faruqi’s website. Follow these updates on various social media platforms for ongoing insights regarding the upcoming legal proceedings and relevant notifications.